Luxembourg vs Spain: Statin use vs. average non-HDL cholesterol levels
Luxembourg
3.3
in 2018
Spain
3.3
in 2018
Luxembourg rank
95th
Spain rank
95th
Statin use vs. average non-HDL cholesterol levels over time
- Luxembourg
- Spain
How they compare
Luxembourg currently reports 3.3 against 3.3 in Spain, a difference of 0.
The two have swapped places 3 times across 39 shared years of data; in 1980 it was Luxembourg ahead.
Luxembourg ranks 95th and Spain ranks 95th of 191 countries.
Across the 4 decades both report, Luxembourg averaged higher in 3 and Spain in 1.
Head to head by decade
| Decade | Luxembourg | Spain | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 4.49 | 4.18 | 0.31 | Luxembourg |
| 1990s | 4.19 | 3.92 | 0.27 | Luxembourg |
| 2000s | 3.75 | 3.68 | 0.07 | Luxembourg |
| 2010s | 3.4 | 3.41 | 0.0111 | Spain |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Luxembourg or Spain?
- Luxembourg, at 3.3 against 3.3 in Spain as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Luxembourg and Spain?
- 0, with Luxembourg ahead.
- How many years of comparable data are there for Luxembourg and Spain?
- 39 years are reported by both, from 1980 to 2018.
- How do Luxembourg and Spain rank globally for statin use vs. average non-hdl cholesterol levels?
- Luxembourg ranks 95th and Spain ranks 95th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.